Fundamentals in Urology (2017)
The Fundamentals in Urology course is designed to apply basic science knowledge and principles in development of treatment algorithms. This 4-day course will provide attendees with valuable skills in developing a rational methodological approach to application of knowledge which will contribute to positive outcomes for patients. Attendees will discover the importance of the study of basic sciences and how it transfers into the lifelong learning process and medical practice. This course is designed to ensure a fundamental knowledge of the "why" behind a broad expanse of general urologic conditions. A thorough knowledge of the basic science behind the treatments will allow for better counseling and education of patients by all clinical urologic practitioners.
Target Audience
- Urology residents
- Allied Health Professionals
Learning Objectives
After attending this course, participants will be able to:
Nephrolithiasis and Infections
- Recognize the basic pathophysiology of nephrolithiasis.
- Identify the indications and options for the medical evaluation of recurrent and first time stone formers.
- Establish an effective algorithm for the medical management of nephrolithiasis.
- Distinguish the appropriate timing of diagnostic methods for treatment of bacteria and fungi in the urinary tract.
Incontinence, Ethics, Obstruction, and Pelvic Pain
- Recall the pathophysiology of pelvic organ prolapse and stress incontinence.
- Describe how to treat pelvic organ prolapse and stress incontinence conditions.
- Review foundational concepts of bioethics.
- Define the meaning of “profession”.
- Discuss key aspects of consent, capacity, research and ethics.
- Identify how to apply consent, capacity, research and ethics to the practice of urology.
- Recognize the role of prophylacitic antibiotics and lower urinary tract imaging for prenatal urinary tract dilation.
- Define the true incidence of IC/BPS and CP/CPPS in the US population.
- Recall what is currently believed about the pathophysiology of chronic pelvic pain.
- Recognize how to use the AUA guidelines to develop a treatment plan for patients with IC/BPS and CP/CPPS.
- Describe current research in pelvic pain and possible new treatment options.
Minimally Invasive Surgery, BPH, Outcomes and Pediatrics
- Identify the physics underlying laser energy, complications occurring due to pneumoperitoneum, and optimizing delivery of shock wave energy.
- Define the medical therapies designed to address benign enlargement of the prostate.
- Explain the basic development of the lower and upper urinary tract including the bladder, kidney and ureters.
- Identify clinical situations that may be encountered if aberrant development occurs in any of the above organ systems.
- Recognize the validity of randomized clinical trials.
- Recognize how to apply the results of outcomes research to clinical practice.
Imaging and Prostate Cancer
- Describe the history of M1 Prostate cancer therapies.
- Identify basics in ADT management.
- Discuss basic science and clinical outcomes of new therapies.
- Identify the appropriate indications for MRI and the basic MRI sequences used in urinary tract imaging.
- Distinguish benign from malignant renal masses.
- Recognize how an MRI of the prostate and urethra can be useful and the key features of prostate tumor on MRI.
Adrenal and Renal Physiology, Bowel Diversions, and Bladder Cancer
- Describe how fundamentals of adrenal anatomy and physiology integrate into the care of the urologic patient.
- Discuss renal physiology for the urologist, especially for the following pathologic states: TUR syndrome, upper urinary tract obstruction, post-obstructive diuresis, pregnancy, renovascular hypertension, and juxtaglomerular tumor.
- Review the major genetic alterations that are present in bladder cancers.
- Define “intrinsic subtypes”.
- Discuss their implications for disease heterogeneity and precision medicine
- Review current understanding of immunotherapy for treatment of bladder cancer.
- Explain rationale for choosing a urinary diversion based on the metabolic derangements associated with each segment of bowel.
Male Infertility, Disorders of Differentiation, and Kidney Cancer
- Explain male reproductive anatomy and physiology.
- Discuss a basic clinical overview of male reproductive medicine and surgery.
- Describe the current clinical and surgical management of all types of localized as well as advanced kidney cancer.
PSA and the Prostate, Neurogenic Bladder, and Reproductive Biology
- Review the current data on the controversies, clinical trials and laboratory testing for prostate cancer screening in asymptomatic men.
- Explain lower urinate tract neurobiology and how disease processes, such as neurologic disease; result in predictable lower urinary tract dysfunction.
- Describe penile anatomy and the physiology of erection.
- Describe the major causes of erectile dysfunction.
- Identify the basic classification, diagnosis and treatment of female sexual dysfunction.
Saturday, June 17, 2017
7:00 – 8:00 am Continental Breakfast and Registration
8:00 – 8:30 am Welcome, Introduction
Tracey L. Krupski, MD, MPH; Jay D. Raman, MD, FACS
Session: Nephrolithiasis and Infections
8:30 – 9:30 am Nephrolithiasis 1: The Physiology, Metabolic Work-up and Treatment of Stones
Glenn M. Preminger, MD
9:30 – 9:45 am Break
9:45 - 10:30 am Nephrolithiasis 2: The Physiology, Metabolic Work-up and Treatment of Stones
Glenn M. Preminger, MD
10:30 – 11:35 am UTIs: Pattern and Pathophysiology
Michel A. Pontari, MD
11:35 – 11:50 am AUA Update
Victor Nitti, MD
11:50 am – 12:50 pm Lunch & Learn with the Experts (Others on Own)
Session: Incontinence, Ethics, Obstruction, and Pelvic Pain
12:50 – 1:55 pm Pelvic Organ Prolapse and SUI: Mechanisms and Mechanics
Victor Nitti, MD
1:55 – 2:50 pm Uro-Ethics
Eric A. Singer, MD
2:50 – 3:00 pm Break
3:00 – 4:05 pm Obstructive Uropathy: Valves and UPJO
C.D. Anthony Herndon, MD, FAAP, FACS
4:05 – 5:15 pm Interstitial Cystitis and Disorders of Pelvic Pain
Robert J. Evans, MD, FACS
6:00 – 7:00 pm Reception
Omni Hotel Atrium
Sunday, June 18, 2017
7:00 – 8:00 am Continental Breakfast
Session: Minimally Invasive Surgery, BPH, Outcomes and Pediatrics
8:00 – 9:05 am Lasers, Laparoscopes, and Lithotripters: The Science of Minimally Invasive Urology
Jay D. Raman, MD, FACS
9:05 – 10:10 am Medical Treatment for BPH
Richard K. Lee, MD
10:10 – 10:25 am Break
10:25 - 11:30 am Embryology and Congenital Anomalies
Patricio C. Gargollo, MD
11:30 am – 12:20 pm Application of Outcomes Research to Urologic Patients
Charles D. Scales Jr., MD
12:20 – 1:20 pm Lunch & Learn with the Experts (Others on Own)
Session: Imaging and Prostate Cancer
1:20 – 1:40 pm AUA Update: Office of Research
Carolyn J.M. Best, PhD
1:40 – 2:30 pm MRI for Urologists I
Afshan Ornan, MD
2:30 – 2:45 pm Break
2:45 – 3:30 pm MRI for Urologists II
Afshan Ornan, MD
3:30 – 4:45 pm Management of Advanced Prostate Cancer: Drugs, Mechanisms, Disease, Epidemiology and Molecular Mechanisms
Michael B. Williams, MD
Monday, June 19, 2017
7:00 – 8:00 am Continental Breakfast
Session: Adrenal and Renal Physiology, Bowel Diversions, and Bladder Cancer
8:00 – 9:05 am Adrenal Physiology
Alexander Kutikov, MD, FACS
9:05 – 10:10 am Renal Physiology Changes in Pathologic States
Necole Marie Streeper, MD
10:10 – 10:25 am Break
10:25 – 11:30 am Basic Science of Bladder Cancer
Trinity J. Bivalacqua, MD, PhD
11:30 am – 12:35 pm Bowel Diversions: Physiology Underlying Electrolyte Abnormalities
Tracey L. Krupski, MD, MPH
Session: Male Infertility, Disorders of Differentiation, and Kidney Cancer
12:35 – 1:35 pm Lunch & Learn with the Experts (Others on Own)
1:35 – 2:40 pm Male Infertility
Puneet Masson, MD
2:40 – 3:45 pm Disorders of Sexual Differentiation
Duong D. Tu, MD
3:45 – 4:00 pm BREAK
4:00 - 5:30 pm Molecular Genetics and Principles of Molecular Therapeutics of Kidney Cancer
W. Marston Linehan, MD
Tuesday, June 20, 2017
7:00 – 8:00 am Continental Breakfast
Session: PSA and the Prostate, Neurogenic Bladder, and Reproductive Biology
8:00 – 9:05 am PSA, Urine Markers and the Science of Cancer Screening
Leonard G. Gomella, MD
9:05 – 10:40 am Lower Urinary Tract Neurobiology and Functional Bladder Disorders
William Stuart Reynolds, MD, MPH
10:40 – 11:45 am Reproductive Biology and Sexual Dysfunction in Men and Women
Ryan Smith, MD
11:45 am Adjourn
Name | Company | Role | Financial |
Trinity J. Bivalacqua, MD | heat biologic
| Scientific Study or Trial
| No
|
photocure | Meeting Participant or Lecturer, Scientific Study or Trial | No | |
Taris | Scientific Study or Trial | No | |
Robert J. Evans, MD
| allergan | Scientific Study or Trial | Yes |
urigen | Investment Interest | Yes | |
TARIS | Scientific Study or Trial | Yes | |
aquinox
| Consultant or Advisor, Scientific Study or Trial
| Yes | |
Patricio C. Gargollo, MD
| Nothing to disclose. | ||
Leonard G. Gomella, MD
| Astellas | Consultant or Advisor | Yes |
Janssen | Consultant or Advisor | Yes | |
Wolters Kluwer | Health Publishing | Yes | |
McGraw Hill | Health Publishing | Yes | |
Merck Manual | Health Publishing | Yes | |
Canadian Journal of Urology | Health Publishing | Yes | |
MDx Health | Consultant or Advisor | Yes | |
Merck Pharmaceuticals | Consultant or Advisor | Yes | |
Bayer | Consultant or Advisor | Yes | |
Mikel L. Gray, Ph.D. | Laborie Medical | Meeting Participant or Lecturer | Yes |
3M Inc. | Consultant or Advisor | Yes | |
C.D. Anthony Herndon, MD, FAAP, FACS
| Nothing to disclose. | ||
Tracey Krupski, MD | Argos | Scientific Study or Trial | No |
NCI- RAZOR | Scientific Study or Trial | No | |
Eleven Biotherapeutics | Scientific Study or Trial | Yes | |
American Cancer Society | Scientific Study or Trial | Yes | |
Alexander Kutikov, MD | UrologyMatch.com LLC | Leadership Position | Yes |
Visible Health, Inc | Leadership Position | Yes | |
Genomic Health, Inc | Consultant or Advisor, Meeting Participant or Lecturer | Yes | |
Novartis, Inc | Consultant or Advisor | Yes | |
Richard K. Lee, MD | Nothing to disclose | ||
W. Marston Linehan, MD | Nothing to disclose. | ||
Puneet Masson, MD | Nothing to disclose. | ||
Victor Nitti, MD | Astellas | Health Publishing, Scientific Study or Trial | No |
Allergan | Health Publishing, Scientific Study or Trial | No | |
Serenity Pharmaceuticals | Investment Interest | Yes | |
Cook Myosite | Scientific Study or Trial | No | |
Medtronic | Scientific Study or Trial | No | |
Afshan Ornan ,M.D. | Nothing to disclose. |
|
|
Gladell Paner, MD | Amirsys, Inc. | Health Publishing | Yes |
Glenn M. Preminger, MD | Boston Scientific | Consultant or Advisor | Yes |
Endourological Society | Leadership Position | Yes | |
UpToDate | Health Publishing | Yes | |
Retrophin | Consultant or Advisor, Meeting Participant or Lecturer | Yes | |
Michel Pontari, MD | Lilly | Consultant or Advisor | Yes |
Aquinox | Consultant or Advisor, Scientific Study or Trial | Yes | |
Jay D. Raman, MD | American Kidney Stone Management | Investment Interest | Yes |
Pacific Edge Biotechnology | Consultant or Advisor, Scientific Study or Trial | No | |
William Stuart Reynolds, MD, MPH | AMAG Pharmaceuticals | Meeting Participant or Lecturer | Yes |
Valeant Pharmaceuticals | Consultant or Advisor, Meeting Participant or Lecturer | Yes | |
Pfizer Pharmaceuticals | Meeting Participant or Lecturer, Other | Yes | |
Charles D. Scales Jr., MD | NIH/National Institute on Aging | Scientific Study or Trial | Yes |
Society of Urology Chairpersons and Program Directors | Scientific Study or Trial | Yes | |
Filament Biosolutions | Scientific Study or Trial | No | |
NIH/ National Institute of Diabetics and Digestive and Kidney Diseases | Scientific Study or Trial | No | |
Gilead | Consultant or Advisor | Yes | |
Astra-Zeneca | Scientific Study or Trial | Yes | |
Eric A. Singer, MD | Nothing to disclose. | ||
Ryan Smith, MD | Nothing to disclose. | ||
Necole M Streeper, M.D. | Nothing to disclose. | ||
Duong D. Tu, M.D. | Nothing to disclose. | ||
Michael B. Williams, M.D. | Astellas | Scientific Study or Trial | No |
Jannsen | Scientific Study or Trial | No | |
Pacific Edge Diagnostics | Consultant or Advisor | Yes |
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation:
- Full Course: The American Urological Association designates this live activity for a maximum of 25.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Pathology AND Urodynamics: The American Urological Association designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Available Credit
- 25.75 AMA PRA Category 1 Credit™
- 25.75 Non-Physician Participation